Penumbra (PEN) Long-Term Investments (2017 - 2018)

Penumbra's (PEN) quarterly Long-Term Investments came in at $2.6 million in Q2 2018, down 20.97% on a QoQ basis from $3.3 million in Q1 2018.

Penumbra (PEN) Long-Term Investments (2017 - 2018) Analysis & Trends

Penumbra (PEN) has 2 years of Long-Term Investments data on file, last reported at $2.6 million in Q2 2018.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $2.6 million in Q2 2018; TTM through Jun 2018 was $2.6 million, a N/A change from a year earlier, with the FY2017 full-year figure at $3.9 million, changed N/A from the prior year.
Long-Term Investments for Q2 2018 stood at $2.6 million, down from $3.3 million in the prior quarter.
Over the last five years, Long-Term Investments for PEN reached as high as $3.9 million in Q4 2017 and fell as low as $2.6 million in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	1.09 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	285.60 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	166.25 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	121.00 Mn
10	Penumbra	12.48 Bn	11.87 Bn	253.41 Mn	-

Download Data